HAP Trading’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-61,326
| Closed | -$1.51M | – | 936 |
|
|
2025
Q2 | $1.49M | Sell |
61,326
-64,659
| -51% | -$1.51M | 0.14% | 92 |
|
|
2025
Q1 | $3.19M | Buy |
125,985
+451
| +0.4% | +$11.8K | 0.34% | 59 |
|
|
2024
Q4 | $3.33M | Buy |
125,534
+82,220
| +190% | +$2.23M | 0.29% | 58 |
|
|
2024
Q3 | $1.25M | Buy |
43,314
+30,181
| +230% | +$880K | 0.14% | 108 |
|
|
2024
Q2 | $367K | Sell |
13,133
-27,315
| -68% | -$752K | 0.04% | 220 |
|
|
2024
Q1 | $1.12M | Sell |
40,448
-5,120
| -11% | -$142K | 0.13% | 115 |
|
|
2023
Q4 | $1.31M | Buy |
45,568
+27,019
| +146% | +$817K | 0.21% | 105 |
|
|
2023
Q3 | $615K | Sell |
18,549
-33,390
| -64% | -$1.18M | 0.1% | 181 |
|
|
2023
Q2 | $1.91M | Buy |
51,939
+27,144
| +109% | +$1.06M | 0.33% | 65 |
|
|
2023
Q1 | $1.01M | Sell |
24,795
-14,005
| -36% | -$605K | 0.16% | 128 |
|
|
2022
Q4 | $1.99M | Sell |
38,800
-46,097
| -54% | -$2.21M | 0.2% | 126 |
|
|
2022
Q3 | $3.71M | Buy |
84,897
+42,890
| +102% | +$2.08M | 0.25% | 95 |
|
|
2022
Q2 | $2.2M | Sell |
42,007
-36,933
| -47% | -$1.88M | 0.11% | 158 |
|
|
2022
Q1 | $4.09M | Buy |
+78,940
| New | +$4.1M | 0.17% | 105 |
|
|
2021
Q4 | – | Sell |
-56,633
| Closed | -$2.81M | – | 2785 |
|
|
2021
Q3 | $2.44M | Sell |
56,633
-359,718
| -86% | -$15.9M | 0.08% | 241 |
|
|
2021
Q2 | $16.3M | Buy |
416,351
+135,638
| +48% | +$5.27M | 0.51% | 27 |
|
|
2021
Q1 | $10.2M | Buy |
280,713
+69,402
| +33% | +$2.46M | 0.54% | 35 |
|
|
2020
Q4 | $7.78M | Buy |
211,311
+161,172
| +321% | +$5.91M | 0.22% | 76 |
|
|
2020
Q3 | $1.75M | Buy |
50,139
+31,718
| +172% | +$1.11M | 0.09% | 175 |
|
|
2020
Q2 | $571K | Buy |
18,421
+3,986
| +28% | +$135K | 0.03% | 397 |
|
|
2020
Q1 | $447K | Buy |
+14,435
| New | +$492K | 0.03% | 362 |
|
|
2019
Q4 | – | Sell |
-45,592
| Closed | -$1.62M | – | 1413 |
|
|
2019
Q3 | $1.55M | Buy |
+45,592
| New | +$1.66M | 0.13% | 141 |
|
|
2019
Q2 | – | Sell |
-16,746
| Closed | -$665K | – | 1301 |
|
|
2019
Q1 | $675K | Buy |
+16,746
| New | +$671K | 0.06% | 236 |
|
|
2018
Q1 | – | Sell |
-22,539
| Closed | -$775K | – | 1137 |
|
|
2017
Q4 | $775K | Buy |
22,539
+5,688
| +34% | +$194K | 0.03% | 315 |
|
|
2017
Q3 | $571K | Buy |
16,851
+4,862
| +41% | +$156K | 0.03% | 343 |
|
|
2017
Q2 | $382K | Sell |
11,989
-9,068
| -43% | -$286K | 0.02% | 404 |
|
|
2017
Q1 | $683K | Sell |
21,057
-19,408
| -48% | -$612K | 0.04% | 296 |
|
|
2016
Q4 | $1.25M | Sell |
40,465
-99,511
| -71% | -$3.04M | 0.06% | 223 |
|
|
2016
Q3 | $4.5M | Buy |
+139,976
| New | +$4.68M | 0.16% | 79 |
|
|
2015
Q4 | – | Sell |
-57,548
| Closed | -$1.81M | – | 1075 |
|
|
2015
Q3 | $1.72M | Sell |
57,548
-16,602
| -22% | -$532K | 0.09% | 205 |
|
|
2015
Q2 | $2.36M | Sell |
74,150
-49,260
| -40% | -$1.61M | 0.14% | 162 |
|
|
2015
Q1 | $4.07M | Buy |
+123,410
| New | +$3.92M | 0.27% | 78 |
|
|
2014
Q2 | – | Sell |
-80,978
| Closed | -$2.31M | – | 1107 |
|
|
2014
Q1 | $2.47M | Buy |
80,978
+13,546
| +20% | +$404K | 0.11% | 156 |
|
|
2013
Q4 | $1.96M | Buy |
+67,432
| New | +$1.96M | 0.06% | 263 |
|
|
2013
Q3 | – | Sell |
-6,834,652
| Closed | -$182M | – | 860 |
|
|
2013
Q2 | $182M | Buy |
+6,834,652
| New | +$189M | 6.14% | 2 |
|
Other funds holding PFE
HAP Trading's PFE Position: Q3 2025 in Review
HAP Trading sold out of Pfizer (PFE) in Q3 2025, closing a stake of 61,326 shares — an estimated $1.51M sold.
HAP Trading first reported a position in PFE in Q2 2013 and held it in 35 quarters. The position peaked at $182M in Q2 2013. 2,812 funds tracked by Wall St. Rank hold PFE as of Q3 2025.
- HAP Trading reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
- HAP Trading sold 61,326 Pfizer shares in Q3 2025, an estimated $1.51M.
- HAP Trading first reported a position in Pfizer in Q2 2013 and held it in 35 quarters.
- HAP Trading's Pfizer position peaked at $182M in Q2 2013.
- 2,812 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.
Based on HAP Trading's 13F filing for Q3 2025, filed 12 Nov 2025.